Phenomune Does Not Exist as a Clinical Product
There is no FDA-approved or clinically recognized product called "Phenomune" or "Phenomune taste-sensitivity kit" in medical practice. Based on the available evidence, this appears to be either a misnamed product or a confusion with research-based taste testing methodologies.
What You May Be Referring To
PTC (Phenylthiocarbamide) Taste Testing for T2R38 Assessment
The evidence suggests you may be asking about PTC taste strip testing used to assess bitter taste receptor T2R38 function, which relates to innate immunity in the upper airways 1, 2, 3.
Key Points:
PTC taste strips assess the functional status of the T2R38 bitter taste receptor, which is expressed in sinonasal cilia and plays a role in detecting bacterial quorum-sensing molecules 3
The test categorizes patients as nontasters, tasters, or supertasters based on their ability to perceive PTC as bitter 2
This correlates with specific TAS2R38 gene polymorphisms (PAV/PAV, PAV/AVI, AVI/AVI variants) 1
Clinical Relevance to Innate Immunity
The T2R38 phenotype has limited but specific clinical utility:
Nontasters (AVI/AVI genotype) have impaired T2R38 function and may experience more severe chronic rhinosinusitis (CRS), particularly in white patients without nasal polyps 1, 2
The receptor activates nitric oxide-dependent innate immune responses when it detects bacterial molecules 3
PTC taste testing may identify patients with poorer innate immune responses in the upper airway 1
How to Use in Clinical Assessment
If you have access to PTC taste strips:
- Administer the taste strip test (takes approximately 4 minutes) 4
- Categorize the patient as nontaster, taster, or supertaster
- Nontasters may benefit from more aggressive monitoring and treatment in CRS without polyps 1, 2
- Consider this as supplementary information only—it does not replace standard diagnostic workup
Critical Limitation: PTC tasting ability provides unique phenotypic information but does not correlate with other subjective or objective measures of smell and taste 2. It should not be used as a general "innate immunity score" across all clinical contexts.
Regarding "Innate Immunity Scores" Generally
The 2022 sepsis guideline 5 discusses monitoring innate immunosuppression in sepsis through:
- Neutrophil function assessment
- Monocyte/macrophage evaluation
- Dendritic cell counts
- Natural killer cell cytotoxicity
However, there is no standardized "innate immunity score" for general clinical use 6. Current approaches lack consistent quantitative criteria and standardization across different clinical contexts.
Bottom line: If someone is marketing a product called "Phenomune," request specific FDA approval documentation and published validation studies before clinical use.